Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Keeping track of Sunshine Biopharma’s dual identity—generic drug revenues today and high-stakes oncology research tomorrow—means wading through hundreds of pages of SEC disclosures. If you have ever searched for “Sunshine Biopharma insider trading Form 4 transactions” or wondered how K1.1 mRNA funding shows up in a quarterly earnings report 10-Q filing, you know the challenge.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment Sunshine Biopharma files with EDGAR, then delivers concise explanations in plain English. Looking for real-time alerts on Sunshine Biopharma Form 4 insider transactions? Need a one-page brief that makes the annual report 10-K simplified? Or perhaps you want the proxy statement executive compensation broken down by cash versus stock grants. It’s all here, refreshed as soon as the SEC stamp appears.
What you can do on this page:
- Track executive stock transactions Form 4 before pivotal trial readouts.
- Compare segment margins with our Sunshine Biopharma earnings report filing analysis.
- Receive instant summaries when a new 8-K material events explained filing details clinical milestones.
- Save hours by understanding Sunshine Biopharma SEC documents with AI rather than combing through footnotes.
Whether you’re modeling how generic sales fund R&D or checking for insider confidence in Adva-27a, our platform offers the comprehensive, real-time coverage professionals expect—now explained simply.
Amendment No. 1 to a Schedule 13G/A reports that three related Altium entities jointly filed a disclosure concerning Sunshine Biopharma, Inc. The filing names the fund, its investment adviser and the fund's general partner and explains their potential relationships to any securities of the issuer.
The filing explicitly reports 0 shares (0%) beneficially owned by each reporting person and states that the securities were not acquired for the purpose of changing or influencing control of the issuer. The document clarifies parties who could be deemed to have a relationship to beneficial ownership while also affirming that no holdings are reported in this statement.
Sunshine Biopharma Inc. reported six-month revenue of $18,311,571, up 8.7% year-over-year, with gross profit of $6,153,292 as cost of goods sold fell to 66.4% of sales from 72.0% a year earlier, reflecting improved procurement and pricing.
The company recorded a net loss of $2,950,605 for the six months, driven in part by a $1,061,809 impairment of certain intangible product licenses and higher consulting and salary costs. Operating cash use was $2,987,267 in the period, while cash and equivalents stood at $10,305,320. Financing activities provided $3,948,372 (including registered direct offering net proceeds of $1,828,596 and warrant exercises), and management states existing cash and expected sales are sufficient to fund operations for the next 24 months. The company disclosed a demand letter from its former Nora Pharma president seeking CAD 7,307,025 (~$5.3M), with no accrual recorded. Outstanding potential dilution includes 15,577,965 Series B warrants (as adjusted) and 4,555,945 common shares issued and outstanding.
FAQ
What is the current stock price of Sunshine Biopharma (SBFMW)?
